Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Sells $623,855.97 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $90.27, for a total value of $623,855.97. Following the transaction, the insider owned 11,305 shares in the company, valued at $1,020,502.35. This represents a 37.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Joanne Quan also recently made the following trade(s):

• On Thursday, January 22nd, Joanne Quan sold 1,822 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $170,047.26.

Mirum Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ MIRM opened at $94.29 on Friday. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $96.84. The business has a 50-day moving average price of $77.33 and a two-hundred day moving average price of $70.64. The firm has a market capitalization of $4.85 billion, a PE ratio of -109.64 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm’s quarterly revenue was up 47.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.30) EPS. As a group, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Analyst Ratings Changes

A number of equities analysts have recently weighed in on MIRM shares. Citizens Jmp upped their price target on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research note on Friday, December 19th. JMP Securities set a $95.00 target price on Mirum Pharmaceuticals in a research report on Wednesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Morgan Stanley boosted their price target on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Finally, Evercore ISI restated an “outperform” rating and issued a $101.00 price objective on shares of Mirum Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $102.58.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently modified their holdings of MIRM. CWM LLC boosted its holdings in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after buying an additional 161 shares during the period. Legal & General Group Plc lifted its position in Mirum Pharmaceuticals by 0.4% during the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock worth $2,189,000 after acquiring an additional 176 shares during the last quarter. MCF Advisors LLC grew its position in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in Mirum Pharmaceuticals by 2.2% in the 2nd quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock valued at $504,000 after buying an additional 215 shares during the last quarter. Finally, Palumbo Wealth Management LLC grew its position in Mirum Pharmaceuticals by 4.2% in the 2nd quarter. Palumbo Wealth Management LLC now owns 5,604 shares of the company’s stock worth $285,000 after purchasing an additional 228 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.